SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Filing Cabinet
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: EepOpp who started this subject6/7/2002 9:47:14 PM
From: EepOpp   of 15
 
09:06 ET DOV Pharmaceutical may benefit from pagoclone failure (DOVP) 4.89: We are hearing Street talk that the failure of pagoclone for IDEV could be a big positive for DOVP, as DOVP's ocinaplon is the only other anti-anxiety drug in late stage trials besides pagoclone that does not cause sedation; hearing ests that the anti-anxiety mkt could be in excess of $1 bln, and that DOVP's ocinaplon will now be first to mkt after pagoclone's failure.
[Briefing.com]

siliconinvestor.com
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News